Associate Professor of Medicine, Massachusetts General Hospital
Hematology
Dr. Karen K. Ballen, MD
|
|
Give Review
Karen Ballen works in the field of Hematology. She researched medicine at Geisel School of Medicine at Dartmouth. Geisel School of Medicine at Dartmouth is ranked 37/29 in Research/PrimaryCare. She received 3 awards: "America's Top Doctors", "Boston Magazine" and "America's Top Doctors for Cancer". Karen K. Ballen, MD is also a published doctor. She has 74 paper published. The most recent paper is: Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. She accepts all Medicare patients.
Publications
- Pediatric-inspired therapy compared to alloGrafting for Philadelphia chromosome-negative adult ALL in first complete remission.
- Indication and management of allogeneic stem Cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
- Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
- Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL.
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed Acute lymphoblastic leukemia.
- Umbilical cord blood transplantation: review of factors affecting the hospitalized patient.
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem Cell transplantation.
- BK polyomavirus reactivation after reduced-intensity double umbilical cord blood Cell transplantation.
- Effect of Cord Blood Processing on Transplant Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation.
- Hospital Length of Stay in the First 100Â Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft S...
- Alternative donors extend transplantation for patients with Lymphoma who lack an HLA matched donor.
- Presentation and outcomes among patients with isolated Myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis.
- Outcomes and management strategies for Graft failure after umbilical cord blood transplantation.
- Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem Cell transpl...
- Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for Acute lymphoblastic leukemia.
- Population-based disparities in survival among patients with core-binding factor Acute myeloid leukemia: A SEER database analysis.
- The Optimal Donor Source for Acute Myeloid Leukemia: Do We Know the Answer?
- EnGraftment syndrome after allogeneic hematopoietic cell transplantation in adults.
- Phase I Study of Urate Oxidase in the Reduction of Acute Graft-vs-Host Disease Following Myeloablative Allogeneic Stem Cell Transplantation.
- Reduced-intensity hematopoietic Cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow tran...
- ATG for cord blood transplant: yes or no?
- Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem Cell transplantation for hematologic malignancies.
- Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and Acute myeloid leukemia (AML).
- A unique PML-RARα rearrangement involving chromosomes 11, 15, and 17 in a patient with Acute promyelocytic leukemia.
- Prostaglandin-modulated umbilical cord blood hematopoietic stem Cell transplantation.
- Risk factors for invasive fungal Disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
- Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome.
- Umbilical cord blood transplantation: the first 25 years and beyond.
- Association between baseline body mass index (BMI) and overall survival among patients over age 60 with Acute myeloid leukemia (AML).
- Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.
- Has umbilical cord blood transplantation for AML become mainstream?
- Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial.
- Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed Acute myeloid leukemia, to assess disease activity and therapeutic response.
- Expression of ñ4ò7 integrin on memory CD8(+) T cells at the presentation of Acute intestinal GVHD.
- The expanding frontier of hematopoietic Cell transplantation.
- Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
- Allogeneic hematopoietic Cell transplantation for advanced polycythemia vera and essential thrombocythemia.
- How to manage the transplant question in myelofibrosis.
- Selection of optimal alternative Graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.
- Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with Leukemia and myelodysplastic syndromes.
- Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor Grafts.
- Cord colitis syndrome in cord-blood stem-Cell transplantation.
- Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal Acute myeloid leukemia (CN-AML) and FLT3ITD.
- Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
- High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin Lymphoma.
- Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Alternative donor transplantation: results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood Grafts.
- Reducing the risk for transplantation-related mortality after allogeneic hematopoietic Cell transplantation: how much progress has been made?
- Second unrelated donor hematopoietic cell transplantation for primary Graft failure.
- Donor-derived second hematologic malignancies after cord blood transplantation.
- Outcome of transplantation for myelofibrosis.
- Race and socioeconomic status influence outcomes of unrelated donor hematopoietic Cell transplantation.
- Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma: a single-institution exp...
- High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
- The national marrow donor program 20 years of unrelated donor hematopoietic Cell transplantation.
- Twenty years of unrelated donor hematopoietic Cell transplantation for adult recipients facilitated by the National Marrow Donor Program.
- Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with Acute myelogenous leukemia.
- Phase I trial of parathyroid hormone to facilitate stem Cell mobilization.
- Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
- Outcomes of 122 diverse adult and pediatric cord blood transplant recipients from a large cord blood bank.
- Treatment-related myelodysplasia/AML in a patient with a history of breast Cancer and an oligodendroglioma treated with temozolomide: case study and review of the lite...
- Double cord blood transplants: filling a niche?
- New trends in umbilical cord blood transplantation.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia.
- Autologous stem-Cell transplantation can be performed safely without the use of blood-product support.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-2004. A 31-year-old man with bilateral testicular enlargement.
- Racial diversity with high nucleated Cell counts and CD34 counts achieved in a national network of cord blood banks.
- Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors.
- Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy.
- Is there a best graft source of transplantation in Acute myeloid leukemia?
- Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters Immune reconstitution after UCBT.
- Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of Myeloid malignancies.
Schools
Dartmouth Medical School
Beth Israel HospHarvard Med School
Brigham and Women39s Hospital
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
Education
-
Brigham and Women's Hospital -
Beth Israel Deaconess Medical Center -
Geisel School of Medicine at Dartmouth
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1821089558 | |
| NPPES Provider LastName | BALLEN | |
| NPPES Provider FirstName | KAREN | |
| NPPES Provider ZIPCode | 021142621 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 247.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1821089558 |
| Last Name Of The Provider | BALLEN |
| First Name Of The Provider | KAREN |
| View All |
Similar Doctors
|
|
Dr. Daniel E. Morganstern, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark S. Stonecypher, MD |
|
|
Dr. Judith C. Lin, MD |
|
|
Dr. Christopher J. Gibson, MD |
|
|
Dr. Roberto Mattii, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane L. Meisel, MD |
|
|
Dr. Daniel G. Tenen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Caron A. Jacobson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy S. Garrett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey A. Morgan, MD |
|
|
Dr. Jason Luke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jill N. Allen, MD |
|
|
Dr. Robert S. Meehan, MD |
|
|
Dr. Julia M. Cunningham, MD |